| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3905148 | Urology | 2007 | 5 Pages |
Abstract
BTX-B had a limited duration of action, with most of its symptomatically beneficial effects wearing off by 10 weeks in most of our patients. The short duration of action for BTX-B suggests it is unlikely to gain widespread use in the treatment of DO.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
G.R. Hirst, A.J. Watkins, K. Guerrero, K. Wareham, S.J. Emery, D.R. Jones, M.G. Lucas,